Supernus Pharmaceuticals
SUPN
43.25
+0.20
+0.46%
Supernus Pharmaceuticals
US · SUPN
#2636 by market cap
Listed 1970
43.25
+0.20
+0.46%
Live - 5344 symbols - heartbeat 512s ago
· 2026-10-08 09:58
Pre-market
42.97
-0.19%
After-hours
43.05
0.00%
- Market cap
- 2.52B
- P/E (TTM)i
- -22.53
- P/Bi
- 2.44
- EPSi
- -0.68
- Div yieldi
- 0.00%
- 52W posi
- 14%
Reader sentiment
Are you bullish or bearish on SUPN?
Anonymous reader poll. Unscientific, not investment advice.
About Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. It offers Trokendi XR, Oxtellar XR, APOKYN, XADAGO, and MYOBLOC products. The company was founded by Jack A. Khattar on March 30, 2005 and is headquartered in Rockville, MD.
- Founded
- 2005
- CEO
- Mr. Jack A. Khattar
- Employees
- 778
- Headquarters
- Rockville, Maryland, United States of America
- Fiscal year end
- 12-31
- Website
- supernus.com
Company profile
- Exchange
- US
- Symbol
- SUPN
- Market-cap rank
- #2636
- Listing date
- 1970-01-01
- Market cap
- 2.52B
- Float cap
- 2.24B
- Shares out
- 58.22M
- Float shares
- 51.84M
Sectors & themes
Quote time 2026-10-08 09:58:08 · For reference only, not investment advice and not tailored to your situation.